Please login to the form below

Not currently logged in
Email:
Password:

Boehringer acquires Actimis

Boehringer Ingelheim has revealed an acquisition deal potentially worth $515m, that could see it take control of US-based biotechnology company, Actimis
Boehringer Ingelheim has revealed an acquisition deal potentially worth $515m, that could see it take control of US-based biotechnology company, Actimis.

The agreement between the two companies sets out the terms of a structured buyout, which is dependent on the progress of trials of AP768, an asthma compound developed by Actimis. Should the candidate drug, currently in phase I studies, be successful during clinical testing and advance to the phase III stage, Boehringer will take control of 100 per cent of Actimis' shares.

"Actimis' compound provides an innovative addition to Boehringer Ingelheim's portfolio of development candidates for the potential treatment of respiratory disease," said Dr Andreas Barner, vice-chairman of the Board Corporate Division Pharma Research, Development and Medicine at the company.

Dr Peter McWilliams, president and acting CEO of Actimis, said that the scientific team at the company "has done a great job in bringing the programme into the clinic and we are excited to have consummated an agreement with a company possessing the expertise and capabilities of Boehringer."

17th June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Rainmaker

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics